首页> 外文期刊>Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association >Two different modalities of iron gluconate i.v. administration: effects on iron, oxidative and inflammatory status in peritoneal dialysis patients.
【24h】

Two different modalities of iron gluconate i.v. administration: effects on iron, oxidative and inflammatory status in peritoneal dialysis patients.

机译:葡萄糖酸铁静脉内注射的两种不同形式。用法:对腹膜透析患者铁,氧化和炎症状态的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Iron deficiency represents an important problem for dialysis patients. Oral iron administration is frequently ineffective, requiring parenteral administration, which may trigger severe side effects due to inflammation and/or peroxidation. The aim of the present study was to clarify the effects of parenteral iron administration on iron, inflammatory and oxidative status in peritoneal dialysis patients and compare two different modalities of injecting ferric gluconate intravenously. METHODS: Twenty peritoneal dialysis patients (10M/10F, mean age 60 +/- 16 years) were given i.v. iron gluconate (62.5 mg) both concentrated (1-2 min, PULSE) and diluted in 100 ml of glucose solution (30 min, SLOW). The interval between the first and second administration was 15-60 days. Blood cell count, serum iron, total iron binding capacity (TIBC), ferritin, C-reactive protein (CRP), reactive oxygen species (ROS) concentrations and total antioxidant capacity (TAC) were measured before iron infusion (T0), after 30 min (T1) and after 24 h (T2). RESULTS: No patient had clinical symptoms during or within an hour of iron administration. Serum transferrin was oversaturated in 25% of cases, no matter how iron was injected. Oxidative and inflammatory status parameters were not affected by iron administration: no difference in CRP, ROS concentrations or TAC was found at any time between PULSE and SLOW group. CONCLUSIONS: Our findings showed that neither inflammation nor peroxidation in peritoneal dialysis patients was clinically triggered by 62.5 mg i.v. iron infusion. Both modalities were equally safe. Therefore, in the absence of clinical side effects, PULSE intravenous administration, being cheaper and not so problematic for outpatients, is preferable to SLOW.
机译:背景:铁缺乏症是透析患者的重要问题。口服铁剂常常无效,需要肠胃外给药,由于炎症和/或过氧化作用,可能引发严重的副作用。本研究的目的是阐明肠胃外施用铁对​​腹膜透析患者铁,炎症和氧化状态的影响,并比较静脉内注射葡萄糖酸铁的两种不同方式。方法:对20例腹膜透析患者(10M / 10F,平均年龄60 +/- 16岁)进行静脉内注射。葡萄糖酸铁(62.5 mg)既浓缩(1-2分钟,脉冲),又在100 ml葡萄糖溶液中稀释(30分钟,缓慢)。第一次和第二次给药之间的间隔为15-60天。在输铁(T0)之前,30天后测量血细胞计数,血清铁,总铁结合能力(TIBC),铁蛋白,C反应蛋白(CRP),活性氧(ROS)浓度和总抗氧化剂能力(TAC)分钟(T1)和24小时(T2)之后。结果:铁剂施用期间或一小时内没有患者出现临床症状。不管注射铁如何,血清转铁蛋白在25%的情况下都过饱和。氧化和炎性状态参数不受铁施用的影响:在PULSE和SLOW组之间的任何时间都没有发现CRP,ROS浓度或TAC的差异。结论:我们的研究结果表明,腹膜透析患者的62.5 mg静脉内注射在临床上既没有引发炎症也没有过氧化。铁输液。两种方式都同样安全。因此,在没有临床副作用的情况下,PULSE静脉内给药便宜且对门诊患者没有问题,因此比SLOW更为可取。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号